A single-blind, randomised, placebo-controlled, 15 day repeated-dose study to evaluate the safety, tolerability and pharmacokinetics of SB-649868 [GSK 649868] and its interaction with the CYP3A4 isoenzyme in healthy male subjects.
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs GSK 649868 (Primary) ; Simvastatin
- Indications Sleep disorders
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 18 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2007 New trial record.